Insulet Appoints Bret Christensen As Chief Commercial Officer

BILLERICA, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the leader in tubeless insulin pump technology with its Omnipod® Insulin Management System, today announced the appointment of Bret Christensen as Chief Commercial Officer. Mr. Christensen will run the Company’s commercial operations, including sales, marketing, customer care, market access and advocacy.

Mr. Christensen joins Insulet from Myriad Genetics, where he most recently served as General Manager of its Preventive Care business unit.

“I am thrilled to welcome a leader of Bret’s caliber to run Insulet’s commercial operations,” said Shacey Petrovic, President and Chief Operating Officer. “Over the past year, Insulet has achieved considerable growth and we remain focused on further penetrating both the diabetes and drug delivery markets. Bret’s extensive commercial expertise will be a tremendous asset as we drive execution of our strategic plan.”

“Insulet has a differentiated platform, a significant growth opportunity and a terrific team,” commented Mr. Christensen. “I am excited to join at a time when the company is rapidly expanding and making such great strides in product innovation.”

About Mr. Christensen:

Mr. Christensen brings more than 20 years of commercial experience to Insulet. He joins the Company from Myriad Genetics, where he served as General Manager of Preventive Care, the company’s largest business unit, leading a team of more than 350 employees across all commercial functions. Prior to Myriad Genetics, Mr. Christensen held a series of executive positions at Hologic Corporation, including Vice President of Sales and Marketing of its Gynecologic Surgical Products division. Prior to Hologic, he led key market development and sales teams at Cytyc Corporation. Mr. Christensen earned a B.S. in Business Management from Utah Valley University and received an MBA from the University of Utah.

About Insulet Corporation:

Insulet Corporation (NASDAQ: PODD) is an innovative medical device company dedicated to making the lives of people with diabetes easier. Through its Omnipod Insulin Management System, Insulet seeks to expand the use of insulin pump therapy among people with insulin-dependent diabetes. The Omnipod is a revolutionary and easy-to-use tubeless insulin pump that provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet's Delivery Systems business also partners with global pharmaceutical and biotechnology companies to adapt the Omnipod technology platform for the delivery of subcutaneous drugs across multiple therapeutic areas. Founded in 2000, Insulet Corporation is based in Billerica, Massachusetts. For more information, please visit: http://www.myomnipod.com.

Forward-Looking Statement:

This press release may contain forward-looking statements concerning Insulet's expectations, anticipations, intentions, beliefs or strategies regarding the future. These forward-looking statements are based on its current expectations and beliefs concerning future developments and their potential effects on Insulet. There can be no assurance that future developments affecting Insulet will be those that it has anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond its control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements, and other risks and uncertainties described in its Annual Report on Form 10-K, which was filed with the Securities and Exchange Commission on February 28, 2017 in the section entitled "Risk Factors," and in its other filings from time to time with the Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should any of its assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Insulet undertakes no obligation to publicly update or revise any forward-looking statements.

Insulet Corporation
Deborah R. Gordon, 978-600-7717
Vice President, Investor Relations and Corporate Communications
dgordon@insulet.com

Back to news